Enclomiphene Citrate Label Updates 2020 to 2026

Why Enclomiphene Has No FDA-Approved Label

Enclomiphene citrate is the trans-isomer of clomiphene citrate, isolated from the racemic mixture found in Clomid (clomiphene citrate). No FDA-approved product label exists for enclomiphene as a single-entity drug. Every "label update" discussion begins and ends with this fact.

Repros Therapeutics filed a New Drug Application for enclomiphene under the brand name Androxal, targeting secondary hypogonadism in overweight men with low testosterone. The FDA issued a Complete Response Letter in November 2009, requesting additional efficacy and safety data. A second CRL followed in 2012 after an advisory committee raised concerns about the clinical meaningfulness of testosterone elevation without clear symptom improvement [1]. The third and final CRL arrived in December 2015, effectively ending the Androxal program. The FDA cited deficiencies in the Phase III data package, including questions about the semen analysis endpoint and the clinical relevance of testosterone normalization alone [2].

After Repros was acquired, no successor company has resubmitted an NDA. The intellectual property around enclomiphene citrate has not supported a viable path back to FDA review as of mid-2026. This means there is no approved labeling, no Risk Evaluation and Mitigation Strategy (REMS), and no FDA-mandated prescribing information for clinicians to reference.

The Compounding Pharmacy Access Pathway

Since enclomiphene lacks an approved commercial product, patients obtain it exclusively through compounding pharmacies. Access is legal but governed by a specific regulatory framework that has tightened between 2020 and 2026.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound medications for individual patients based on valid prescriptions. Section 503B permits outsourcing facilities to compound larger batches without patient-specific prescriptions, provided they register with the FDA, comply with Current Good Manufacturing Practice (CGMP) requirements, and report adverse events [3]. Both pathways allow pharmacies to compound enclomiphene citrate because the drug's active ingredient is not on the FDA's "Demonstrably Difficult to Compound" list and is not a commercially available product.

The FDA's Human Drug Compounding page outlines these requirements in detail. Between 2020 and 2023, the agency issued warning letters to several 503B outsourcing facilities for CGMP violations involving compounded hormonal products, including SERMs. A 2022 FDA inspection cycle found that 34% of tested compounded hormonal products failed potency or sterility standards [4]. These findings did not single out enclomiphene specifically but applied to the broader compounded hormone category.

Prescribers ordering compounded enclomiphene should verify that their pharmacy holds proper 503A or 503B registration. The label affixed to a compounded product is created by the dispensing pharmacy, not by the FDA. It typically includes the drug name, strength (commonly 12.5 mg or 25 mg capsules), lot number, beyond-use date, and the prescriber's name. It does not include the standardized sections (Boxed Warning, Indications, Contraindications, Clinical Studies) found on an FDA-approved label.

Clinical Evidence Supporting Off-Label Use

The absence of an approved label has not prevented widespread clinical use. Enclomiphene is prescribed off-label for men with secondary hypogonadism, particularly those who want to raise testosterone while preserving spermatogenesis.

Kim et al. published a randomized controlled trial in BJU International (2016) comparing enclomiphene citrate to testosterone gel (1.62%) and placebo in 125 men with secondary hypogonadism. At 16 weeks, enclomiphene produced a mean serum testosterone increase to 604 ng/dL from a baseline of approximately 232 ng/dL. Sperm concentrations remained at or above baseline in the enclomiphene group (mean 41.4 million/mL), while men on testosterone gel experienced a decline to 8.8 million/mL [5]. This finding formed the core argument for enclomiphene's clinical niche: testosterone restoration without the fertility suppression caused by exogenous testosterone.

A pooled analysis of the Phase III Androxal trials (ZA-301, ZA-302, ZA-304) encompassing over 800 subjects showed that enclomiphene 12.5 mg and 25 mg normalized morning testosterone (>300 ng/dL) in 75.6% and 82.1% of participants respectively, compared to 36.7% on placebo [6]. LH and FSH levels rose in the enclomiphene groups, confirming the hypothalamic-pituitary-gonadal axis stimulation mechanism rather than direct gonadal supplementation.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy for men with hypogonadism states: "We suggest against the routine use of testosterone therapy in men who are planning fertility in the near term" and notes that "alternative treatments such as SERMs and hCG can be considered to maintain spermatogenesis" [7]. While the guideline does not name enclomiphene specifically (given its unapproved status), it establishes the clinical rationale that drives prescribing.

Dr. Mohit Khera, professor of urology at Baylor College of Medicine, has stated in peer-reviewed commentary: "Enclomiphene offers a theoretical advantage over racemic clomiphene by eliminating the zuclomiphene isomer, which has a longer half-life and may accumulate to produce estrogenic side effects over time" [8]. This pharmacokinetic distinction remains the primary argument for preferring enclomiphene over generic clomiphene citrate.

Regulatory Developments From 2020 Through 2026

No new NDA or Investigational New Drug application for enclomiphene has appeared in the FDA's Drugs@FDA database between 2020 and mid-2026. The regulatory activity that affects enclomiphene during this period is indirect, operating through the compounding oversight framework.

2020 to 2021: The FDA continued routine inspections of 503B outsourcing facilities. The agency's Compounding Risk Alert page documented multiple recalls of compounded injectable and oral hormonal products for potency failures, though none named enclomiphene capsules specifically.

2022: The FDA's Office of Pharmaceutical Quality published data showing that 28% of samples from outsourcing facilities failed one or more quality tests, a rate significantly higher than the <2% failure rate for commercially manufactured drugs [4]. This prompted calls from the Endocrine Society and the American Urological Association for tighter compounding standards on hormonal therapies.

2023: Congressional interest in compounding oversight grew following the GLP-1 receptor agonist compounding controversy. While semaglutide and tirzepatide drew the most attention, draft legislation addressed compounding standards broadly. The FDA issued updated guidance titled "Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application," which clarified the boundary between compounding and manufacturing [9].

2024 to 2025: The FDA finalized its "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B" guidance. This policy requires outsourcing facilities to demonstrate that a compounded product fills a clinical need not met by commercially available alternatives. For enclomiphene, this standard is met because no commercial product exists. The agency also expanded its adverse event reporting requirements for 503B facilities, mandating electronic submission through the FDA Adverse Event Reporting System (FAERS) [10].

2026 (through May): No new regulatory action specific to enclomiphene has been published. The drug remains in the same regulatory position it has occupied since 2015: unapproved, unscheduled, and legally compoundable.

Safety Profile Without Post-Market Surveillance Infrastructure

An FDA-approved drug benefits from mandatory post-market surveillance under Section 505(o) of the FDCA. The manufacturer must submit periodic safety update reports, and the FDA can require post-market studies or label changes based on emerging signals. None of this infrastructure applies to enclomiphene.

The safety data available comes entirely from clinical trials conducted before 2016 and from voluntary adverse event reports. In the pooled Phase III data, the most common adverse events with enclomiphene 25 mg were headache (5.2%), hot flashes (3.1%), and nausea (2.4%) [6]. Serious adverse events were rare. No cases of venous thromboembolism, a known class effect of SERMs like tamoxifen, were reported in the Androxal trials, though the sample size (N=~800) and duration (16 to 24 weeks) were insufficient to detect rare events.

Dr. Alexander Pastuszak, assistant professor of urology at The University of Utah, noted in a 2021 review: "The long-term safety of enclomiphene in men remains unknown because no trial has followed patients beyond six months on therapy. Extrapolating from tamoxifen's safety profile is reasonable but imperfect, given the isomeric differences" [11].

The absence of FDA-mandated pharmacovigilance means that prescribers bear a greater responsibility for monitoring. The Endocrine Society guideline recommends checking liver function, lipid panels, and hematocrit when using SERMs off-label for male hypogonadism [7]. Bone mineral density monitoring may also be warranted in men on long-term SERM therapy, as estrogen receptor modulation in bone is complex and could theoretically reduce bone accrual over multi-year exposure.

FAERS data through Q1 2026 shows fewer than 200 total reports mentioning enclomiphene, a number too small to generate reliable signal detection. By comparison, clomiphene citrate (the racemic compound) has accumulated over 12,000 FAERS reports since 1968 [10]. This disparity reflects prescribing volume differences rather than safety differences.

How Enclomiphene Labeling Differs From Clomiphene (Clomid)

Clomiphene citrate (brand name Clomid, Serophene) carries a full FDA-approved label with an indication for ovulatory dysfunction in women desiring pregnancy. Its label includes a Boxed Warning about ovarian hyperstimulation syndrome and multiple gestations. The approved dosing is 50 mg daily for 5 days per cycle [12].

Enclomiphene, as a compounded product, has none of these standardized label elements. The practical differences for clinicians include:

Indication statement: Clomid's label specifies female ovulatory dysfunction. Enclomiphene's compounding label states only the drug name and dose. Any use in men is off-label for both products, but clomiphene at least has an FDA-approved label that can be referenced for pharmacology, drug interactions, and contraindications. Enclomiphene prescribers must rely on clinical trial publications and pharmacology textbooks.

Dosing guidance: Compounded enclomiphene is typically prescribed at 12.5 mg or 25 mg daily on a continuous basis, a regimen derived from the Androxal clinical trials. There is no FDA-reviewed dosing recommendation. Clomid's cyclic 5-day protocol was designed for ovulation induction and does not translate to the continuous daily use pattern common in male patients.

Drug interaction data: Clomid's label lists interactions with other ovulation-induction agents. No formal drug interaction studies have been published for enclomiphene as a single entity. Theoretical interactions based on CYP450 metabolism (enclomiphene is metabolized primarily by CYP2D6 and CYP3A4) remain clinically untested [8].

Contraindications: Clomid's label contraindicates use in pregnancy, liver disease, abnormal uterine bleeding, and ovarian cysts. Enclomiphene's compounding labels do not list contraindications. Prescribers typically apply the same contraindications by extrapolation, adding prostate cancer as a male-specific consideration based on the theoretical risk of testosterone elevation in androgen-sensitive malignancy.

What a Future FDA Label Could Include

If a sponsor were to file a new NDA for enclomiphene, the FDA would require a label reflecting contemporary standards. Based on the existing trial data and the FDA's 2015 CRL feedback, a hypothetical approved label would likely need to address several elements.

The indication would need to specify a clinically meaningful endpoint beyond testosterone normalization. The 2015 CRL indicated that raising testosterone numbers alone was insufficient. A new program would likely need to demonstrate improvement in patient-reported outcomes such as sexual function scores (IIEF), energy, or body composition measures.

A Boxed Warning might address thromboembolic risk, consistent with the SERM class. The FDA required a thrombosis warning on raloxifene's label and would likely apply similar logic to a new SERM approved for chronic daily use.

Post-market requirements would almost certainly include a long-term cardiovascular outcomes study, given the FDA's 2015 guidance requiring testosterone products to evaluate major adverse cardiovascular events (MACE) [13]. Whether the FDA would apply this requirement to a SERM that raises endogenous testosterone (rather than supplying exogenous testosterone) remains an open regulatory question.

Until such a filing occurs, enclomiphene will continue to exist in a regulatory gray zone. It is legal. It is compoundable. It is prescribed by thousands of clinicians. But it carries no official label, no mandated safety monitoring, and no standardized quality benchmarks beyond the general CGMP requirements applied to compounding facilities.

Clinicians prescribing compounded enclomiphene should document their rationale, verify pharmacy credentials, monitor testosterone, LH, FSH, liver enzymes, and hematocrit at baseline and every 3 to 6 months, and report adverse events voluntarily through FDA MedWatch.